Form 4: Baker Bros. Affiliates Report Grant of 76,000 Stock Options to Director at Prelude Therapeutics

Baker Bros. Advisors and its affiliates have reported the grant of 76,000 non-qualified stock options to Dr. Paul C. Scherer, a director of Prelude Therapeutics Inc., with a strike price of $1.04 per share.

Summary

• Baker Bros. Advisors LP and its affiliates, including 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, Felix J. Baker, and Julian C. Baker, reported the acquisition of 76,000 non-qualified stock options in Prelude Therapeutics Inc. (PRLD).
• The options were granted to Dr. Paul C. Scherer, a director of Prelude Therapeutics and a full-time employee of Baker Bros. Advisors (GP) LLC, on June 12, 2025.
• The strike price for these options is $1.04 per share.
• The options vest on the earlier of the first anniversary of the grant date (June 12, 2026) or the date of the next annual meeting of stockholders, contingent on Dr. Scherer's continued service on the board or an earlier change in control.
• The options are set to expire on June 11, 2035.
• The grant was made pursuant to Prelude Therapeutics' 2020 Stock Incentive Plan, as Amended and Restated.
• The reporting persons, including Julian C. Baker and Felix J. Baker, hold an indirect pecuniary interest in these options through their ownership interests in 667, L.P. and Baker Brothers Life Sciences, L.P.
• Baker Bros. Advisors retains complete and unlimited discretion and authority over the investment and voting power of these securities.

Sentiment

Score: 6

Explanation: The document reports a standard equity compensation grant to a director, which is generally a neutral event. However, the grant of options at a specific strike price to a director representing a significant investor like Baker Bros. can be seen as a positive signal of continued alignment and commitment, slightly leaning towards positive.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, potentially incentivizing long-term performance.
• The options were granted at a strike price of $1.04, which could be seen as a low entry point if the company's stock price appreciates significantly.

Risks

• The value of the stock options is dependent on the future performance of Prelude Therapeutics' common stock, which is subject to market fluctuations and company-specific risks.
• Vesting of the options is contingent on Dr. Scherer's continued service on the board, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedule and expiration date of the granted options.

Management Comments

• "Dr. Paul C. Scherer, a full-time employee of Baker Bros. Advisors LP, is a director of Prelude Therapeutics Incorporated (the 'Issuer')."
• "By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer."
• "Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."
• "Pursuant to the policies of the Adviser, Dr. Scherer does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities."

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industry where directors, especially those representing significant institutional investors like Baker Bros. Advisors, receive equity compensation to align their interests with the company's long-term success. Baker Bros. Advisors is a prominent healthcare-focused investment firm, and their continued involvement and equity grants to their representatives on portfolio company boards are common.

Comparison to Industry Standards

• Not applicable, as this document is a specific transaction report for a single company and does not provide comparative financial or operational data against industry benchmarks or competitors.

Corporate Governance

Related Party Transactions

• The grant of 76,000 non-qualified stock options to Dr. Paul C. Scherer, a director of Prelude Therapeutics, is a related party transaction as Dr. Scherer is also a full-time employee of Baker Bros. Advisors (GP) LLC, which is affiliated with significant shareholders (Baker Bros. Advisors LP, 667, L.P., Baker Brothers Life Sciences LP, Felix J. Baker, and Julian C. Baker) who are also deemed 10% owners and directors by deputization.
• The beneficial ownership of these options is indirectly held by 667, L.P. and Baker Brothers Life Sciences, L.P., funds advised by Baker Bros. Advisors LP, further solidifying the related party nature of the transaction.

Stakeholder Impact

• Shareholders: The grant of stock options to a director, particularly one representing a significant institutional investor, can be viewed positively as it aligns the director's long-term interests with shareholder value creation. However, it also represents potential future dilution upon exercise.
• Employees: Dr. Scherer, as an employee of Baker Bros. Advisors (GP) LLC, receives compensation for his board service, though the pecuniary interest in the options accrues to the Baker Bros. funds.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the date of the next annual meeting of stockholders, subject to Dr. Scherer's continued service.
• The options will expire on June 11, 2035, unless exercised prior to that date.

Key Dates

Keywords

Prelude Therapeutics Inc., PRLD, SEC Form 4, stock options, insider transaction, Baker Bros. Advisors, director compensation, equity grant, beneficial ownership, stock incentive plan